We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo Medica 2024 Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Sebia Presents Innovative Solutions for Screening and Diagnostics

By LabMedica International staff writers
Posted on 22 May 2023

Sebia (Lisses, France) is showcasing its innovative solutions for screening and diagnostics in oncology, metabolic diseases, genetic disorders and autoimmune diseases at WorldLab–EuroMedLab Roma 2023.

At EuroMedLab Rome 2023, Sebia is highlighting the new Alegria 2 instrument, a fully automated, sample-to-result solution. The instrument utilizes ORGENTEC’s unique and comprehensive Alegria Monotest portfolio, boasting over 100 parameters. A key distinguishing feature of the Alegria system is its flexibility to run any test from the wide ORGENTEC portfolio at any given time. Physicians can request tailor-made biomarker profiles to be analyzed for individual patients, ensuring the best possible patient care.


Image: The new fully automated Alegria 2 instrument (Photo courtesy of Sebia)
Image: The new fully automated Alegria 2 instrument (Photo courtesy of Sebia)

Sebia is presenting its CAPILLARYS 3 range of capillary electrophoresis (CE) instruments, designed for complete automation, rapid protein separation, and high resolution. The Sebia CE instruments are equipped with several parallel capillaries, enabling multiple analyses to be carried out simultaneously, offering scalable throughput. The Sebia CAPILLARYS instruments are currently the most widely used CE systems in clinical labs globally. Alongside its CE capabilities, Sebia is highlighting its gel technique-based solutions. These are implemented on the HYDRASYS instruments to separate hemoglobins and detect major hemoglobin variants via electrophoresis on alkaline agarose gels.

Leveraging its extensive experience in CE technology, Sebia has also adapted it for HbA1c testing, which is being showcased at WorldLab–EuroMedLab Roma 2023. This cutting-edge technology offers labs and clinicians accurate and significant results, enhancing patient management. The clear and precise separation of different hemoglobin fractions enables accurate HbA1c measurement due to the high-resolution separation capabilities of the capillary instruments. Given Sebia’s wide offering of capillary instruments, laboratories have the freedom to choose the platform that best suits their needs, ranging from a benchtop standalone instrument to the TLA configuration.

Related Links:
Sebia


New
Gold Member
C-Reactive Protein Reagent
CRP Ultra Wide Range Reagent Kit
Antipsychotic TDM AssaysSaladax Antipsychotic Assays
New
Liquid Based Cytology Production Machine
LBP-4032
New
Nuclear Matrix Protein 22 Test
NMP22 Test

Latest EUROMEDLAB 2023 News

DIESSE Diagnostica Unveils CHORUS EVO Immunochemistry Analyzer

LGC Clinical Diagnostics Demonstrates Lab Solutions and Processes to Enhance QC Efficiencies

LumiraDx Demonstrates Fast, High Performance, Portable POC Diagnostic Solution